117 reports of this reaction
3.0% of all GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE reports
#4 most reported adverse reaction
HEADACHE is the #4 most commonly reported adverse reaction for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, manufactured by RB Health (US) LLC. There are 117 FDA adverse event reports linking GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE to HEADACHE. This represents approximately 3.0% of all 3,854 adverse event reports for this drug.
Patients taking GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 117 FDA reports for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 3.0% of all adverse event reports for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, making it a notable side effect.
If you experience headache while taking GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.